Horizon Discovery Group plc Block Listing Six Monthly Return (1517U)

TIDMHZD

RNS Number : 1517U

Horizon Discovery Group plc

27 July 2020

Horizon Discovery Group plc

27 July 2020

Horizon Discovery Group plc

Block Listing Six Monthly Return

27 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon") provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name of applicant:         Horizon Discovery Group plc 
 Name of scheme(s):         a) Horizon Discovery Limited Enterprise Management 
                             Incentive Share Option Scheme 
                             b) Horizon Discovery Group plc Long Term Incentive 
                             Plan 
                             c) Horizon Discovery 2014 Sharesave Scheme 
                             d) Horizon Discovery Group plc US Employee Stock 
                             Purchase Plan 
                           ---------------------------------------------------- 
 Period of return           From 26 January 2020 to 25 July 2020 
  (from / to): 
                           ---------------------------------------------------- 
 Number of securities       Total of 3,000,000 ordinary shares of 1p each, 
  admitted and               admission date 26 July 2017, split: 
  date of admission          a) 1,398,000 
                             b) 1,392,000 
                             c) 110,000 
                             d) 100,000 
                             Further 500,000 ordinary shares of 1p each, 
                             admission date 27 July 2018, split: 
                             a) 0 
                             b) 150,000 
                             c) 150,000 
                             d) 200,000 
                             Further 1,500,000 ordinary shares of 1p each, 
                             admission date 28 October 2019, split: 
                             a) 0 
                             b) 500,000 
                             c) 500,000 
                             d) 500,000 
                           ---------------------------------------------------- 
 Balance of unallotted      Total of 2,983,644 ordinary shares of 1p each, 
  securities under           split: 
  schemes from               a) 602,425 
  previous return:           b) 1,352,676 
                             c) 567,971 
                             d) 460,572 
                           ---------------------------------------------------- 
 Less: Number               Total of 534,264 ordinary shares of 1p each, 
  of securities              split: 
  issued/allotted            a) 478,340 
  under scheme(s)            b) 52,760 
  during period:             c) 3,164 
                             d) 0 
                           ---------------------------------------------------- 
 Equals: Balance            Total of 2,449,380 ordinary shares of 1p each, 
  under scheme(s)            split: 
  not yet issued/allotted    a) 124,085 
  at end of period:          b) 1,299,916 
                             c) 564,807 
                             d) 460,572 
                           ---------------------------------------------------- 
 

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield/Duncan Monteith

Tel: [phone]

Consilium Strategic Communications (UK Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development. Horizon's portfolio of tools and services is built on decades of experience in altering the expression of genes across mammalian and human cell types to provide cell engineering tools and services to customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Horizon's offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine. Horizon's customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organisations and academic researchers across the globe.

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BLRKKOBPOBKKFOB

(END) Dow Jones Newswires

July 27, 2020 04:00 ET (08:00 GMT)